The FLOTILLA study allows people who participated in earlier studies of encorafenib and binimetinib to continue receiving these medicines if they are still benefiting from them. The main goal is to provide ongoing access to these treatments and ensure safety for participants. Those who had already stopped receiving treatment in previous studies cannot join this study. Participants may receive the same doses and schedules as before for up to about 5 years.
This trial's ID number is NCT05203172. It is a Phase 4 study looking at how well the treatments work and their safety. The trial is regulated by the FDA, and it aims to include about 75 participants.
Who can join
This study is open to adults aged 18 and older, including all genders. To join, you must have been part of earlier studies using encorafenib or binimetinib and still be benefiting from the treatment. There are some medical conditions that may prevent participation, but the trial team will confirm eligibility.
Condition
Solid Tumors
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive one of five treatment options based on what they had in previous studies. They may receive binimetinib only, encorafenib only, both encorafenib and binimetinib, or combinations of these with other treatments like ribociclib or cetuximab. Everyone will receive treatments they were previously on, and they will not be placed in different groups by chance.
Where
This trial is enrolling at 18 locations. Recruiting sites are listed first.
Barnes-Jewish Hospital
St Louis, Missouri
Recruiting
Duke Cancer Center
Durham, North Carolina
Recruiting
Emory University Hospital
Atlanta, Georgia
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia
Recruiting
HealthPartners Cancer Research Center
Saint Paul, Minnesota
Recruiting
Investigational Chemotherapy Service
Durham, North Carolina
Recruiting
Investigational Drug Service Emory University Clinic